Individual treatment of cystic fibrosis by using intestinal organoids

Florijn Dekkers (Utrecht, Netherlands)

Source: International Congress 2015 – Advancing therapies for cystic fibrosis
Session: Advancing therapies for cystic fibrosis
Session type: Hot topics
Number: 1736

WebcastSlide presentationMultimedia files

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Florijn Dekkers (Utrecht, Netherlands). Individual treatment of cystic fibrosis by using intestinal organoids. International Congress 2015 – Advancing therapies for cystic fibrosis

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Intestinal organoids to model cystic fibrosis
Source: Eur Respir J, 54 (1) 1802379; 10.1183/13993003.02379-2018
Year: 2019



Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis
Source: Eur Respir J, 57 (1) 1902426; 10.1183/13993003.02426-2019
Year: 2021



Cystic fibrosis and intestinal organoids
Source: ERN-LUNG 2021: Cystic fibrosis and intestinal organoids
Year: 2021

Investigation of the status of cystic fibrosis airway epithelial cells
Source: Annual Congress 2008 - Multigenic expression analyses: a guide for diagnosis and therapy
Year: 2008


Neomacrolides in cystic fibrosis
Source: Annual Congress 2012 - Non-antibiotic effects of macrolides in lung disease
Year: 2012


Distribution and characterisation of lung mast cells in cystic fibrosis
Source: Annual Congress 2009 - Airway inflammation and host defence
Year: 2009

Lung stem cells and therapy for cystic fibrosis
Source: Eur Respir Monogr 2021; 91: 306-321
Year: 2021


Bacterial infection and lung function in patients with cystic fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 615s
Year: 2005

Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells
Source: Eur Respir J 2015; 45: 428-439
Year: 2015



Proteomics characterisation of nasal epithelial cells in cystic fibrosis
Source: Annual Congress 2009 - New results in molecular pathology and functional genomics of non-neoplastic lung diseases
Year: 2009


What damages the cystic fibrosis lung epithelium: host or microbe?
Source: Virtual Congress 2021 – Innate immunity and lung epithelial repair: what really happens?
Year: 2021


Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function
Source: Eur Respir J, 52 (3) 1702529; 10.1183/13993003.02529-2017
Year: 2018



Is mitochondria morphology altered in epithelial cells with cystic fibrosis?
Source: Eur Respir J 2003; 22: Suppl. 45, 501s
Year: 2003

Long-term clearance from small airways in patients with cystic fibrosis
Source: Eur Respir J 2005; 25: 317-323
Year: 2005



Expansion of small sputum macrophages in cystic fibrosis airways
Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools
Year: 2008


Targeting CFTR as a therapy for cystic fibrosis
Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung
Year: 2010

Update on pancreatic and liver disease in cystic fibrosis
Source: Virtual Congress 2020 – Updates in cystic fibrosis
Year: 2020